Publications

1. GVS assessment of sodium zirconium cyclosilicate (Lokelma®) for the treatment of hyperkalemia

   The National Health Care Institute has completed its assessment whether sodium zirconium cyclosilicate (Lokelma®) is ...

   Report | 12-02-2021

2. Package advice multiple myeloma

   Several combination therapies that are used to treat multiple myelomain are placed in the lock procedure for expensive medicinal ...

   Report | 11-02-2021

3. GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease

   The National Health Care Institute has completed its assessment whether opicapone (Ongentys®) is interchangeable with a product ...

   Report | 03-02-2021

4. GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria

   The National Health Care Institute has completed its assessment whether givosiran (Givlaari®) is interchangeable with a product ...

   Report | 02-02-2021

5. GVS assessment oxybutynin intravesical solution (Vesolox®)

   Zorginstituut Nederland has completed its assessment whether oxybutynin intravesical solution (Vesolox®) 1mg/ml is ...

   Report | 18-01-2021

6. GVS advice mexiletine (Namuscla®)

   The National Health Care Institute has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable ...

   Report | 13-01-2021

7. Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism

   Zorginstituut Nederland recommends the minister of Medical Care that rhPTH 1-84 (Natpar®) be designated as a potential candidate ...

   Letter | 21-12-2020

8. GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis

   The National Health Care Institute has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product ...

   Report | 16-12-2020

9. GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections

   Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...

   Report | 15-12-2020

10. GVS assessment - extension of further conditions for nintedanib (Ofev®)

    The National Health Care Institute has completed its assessment of the possible extension of the further conditions for ...

    Report | 15-12-2020